Moolec Science Limited announced the completion of the first phase of industrialization for its GLASO safflower platform, following a record‑setting 2025 campaign that exceeded internal forecasts and delivered a 57% year‑over‑year yield increase over 2024.
The 2025 campaign produced a 45% gamma‑linolenic acid (GLA) concentration and validated high‑purity GLA output for the first time, confirming that the platform can operate at commercial scale with the same performance achieved in pilot trials.
"The 2025 campaign not only confirmed leading GLA concentrations, but also delivered a level of output that exceeded all expectations. Our focus now is clear: complete the industrialization pathway, scale through the 2026 campaign, and expand the platform into new verticals," said CEO Alejandro Antalich.
Achieving approximately 45% GLA concentration at commercial scale demonstrates that Moolec’s technology is not only scientifically differentiated but also operationally executable within existing U.S. agricultural and processing infrastructure. The high purity and concentration position the company to supply premium lipids to dietary supplement and nutritional formulation markets while opening a new revenue stream in renewable energy feedstocks planned for 2026.
The milestone is a critical step toward full commercial deployment of the GLASO product line. It validates the platform’s agronomic and processing performance at scale, supports the company’s strategy to capture high‑value applications, and provides a tangible foundation for the planned expansion into energy markets.
While Moolec continues to navigate broader financial challenges, the successful industrialization of GLASO represents a significant operational achievement that strengthens its competitive position and underpins future growth prospects.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.